Hemab Secures $157M to Address 'Underserved' Blood Diseases
Hemab, a startup with multiple medicines in testing and development, aims to become the "ultimate coagulation disorders company," according to its CEO.
Innovation in hemophilia has seen significant advancements over the last decade, with the introduction of longer-lasting therapies, antibody drugs, and gene therapies, improving patients' ability to control spontaneous bleeds.
However, progress in other bleeding diseases, such as Glanzmann thrombasthenia, Von Willebrand, and Factor VII deficiency, has been slower due to questions about market size and the need for more complex innovations.
These disorders require more "complex innovations and bioengineering" to develop better treatment options, said Sorensen.
Despite these challenges, Hemab's efforts may mark a turning point in addressing these underserved blood diseases.
Author's summary: Hemab raises $157M to tackle underserved blood diseases.
More News
- Photoshop CS6 tutorial: Color lookup
- Kayla - Two warriors. One outcome. Who you got??
- Lookup Field - Overview in Airtable
- UFC 323’s Edson Barboza doesn’t regret featherweight move but ‘I look back and see how sick I was getting’
- Quotes of the Day - Insightful Reflections
- The Number Of Jaguar Recalls For 2025 (So Far) May Surprise You
- It goes, boys! and Other Great Climbing Quotes
- Kayla Harrison is a very interesting case
- 'Fuzzy buildup,' moldy peppers: Latest Kansas City-area restaurant inspections
- Find Out Which Infiniti Recall Affected Nearly Half A Million Cars